MCID: TCL027
MIFTS: 51

T-Cell Acute Lymphoblastic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for T-Cell Acute Lymphoblastic Leukemia

MalaCards integrated aliases for T-Cell Acute Lymphoblastic Leukemia:

Name: T-Cell Acute Lymphoblastic Leukemia 12 36 29 6 15 17
Precursor T-Lymphoblastic Lymphoma/leukemia 12
Leukemia, Acute, Lymphoblastic, T-Cell 39
Leukemia, T-Cell Acute Lymphoblastic 39
Precursor T Lymphoblastic Leukemia 12
T-Cell Acute Lymphocytic Leukaemia 12
T Acute Lymphoblastic Leukemia 12
Acute T Cell Leukaemia 12
Leukemia, Acute T-Cell 39
Acute T Cell Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5603
KEGG 36 H00002
MeSH 43 D015459
NCIt 49 C3184
SNOMED-CT 67 110007008 77430005
ICD10 32 C91.5
UMLS 71 C0023493

Summaries for T-Cell Acute Lymphoblastic Leukemia

KEGG : 36 Acute lymphocytic leukemia (ALL) is a clonal stem cell malignancy of excessive lymphoblast proliferation. It is now understood that ALL and lymphoblastic lymphoma are the same disease entities at the morphologic and immunophenotypic levels and classified as either B- and T-cell lymphoblastic leukemia/lymphoma (B-ALL and T-ALL). T-ALL comprises 15% of paediatric and 25% of adult ALL cases. T cell transformation is a multi-step process in which different genetic alterations cooperate to alter the normal mechanisms that control cell growth, proliferation, survival, and differentiation during thymocyte development. In this context, constitutive activation of NOTCH1 signaling is the most prominent oncogenic pathway in T cell transformation. In addition, T-ALLs characteristically show the translocation and aberrant expression of transcription factor oncogenes. These oncogenic transcription factors include T-cell leukaemia homeobox protein 1 (TLX1 also known as HOX11), TLX3 (HOX11L2), LYL1, TAL1 and MLL.

MalaCards based summary : T-Cell Acute Lymphoblastic Leukemia, also known as precursor t-lymphoblastic lymphoma/leukemia, is related to precursor t-cell acute lymphoblastic leukemia and leukemia, acute lymphoblastic. An important gene associated with T-Cell Acute Lymphoblastic Leukemia is BAX (BCL2 Associated X, Apoptosis Regulator), and among its related pathways/superpathways are Transcriptional misregulation in cancer and NF-kappaB Signaling. The drugs Prednisone and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include t cells, myeloid and b cells, and related phenotypes are cellular and hematopoietic system

Related Diseases for T-Cell Acute Lymphoblastic Leukemia

Diseases related to T-Cell Acute Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 214, show less)
# Related Disease Score Top Affiliating Genes
1 precursor t-cell acute lymphoblastic leukemia 35.2 TLX3 TLX1 TAL1 NUP98 NOTCH1 LYL1
2 leukemia, acute lymphoblastic 34.2 TLX1 TAL1 NOTCH1 NALT1 LMO2 IL2
3 leukemia 32.5 TLX3 TLX1 TAL2 TAL1 NUP98 NOTCH1
4 t-cell lymphoblastic leukemia/lymphoma 32.2 TLX1 TAL1 NOTCH1 LMO2 LMO1 LCK
5 lymphoblastic lymphoma 32.1 TLX1 TAL1 NOTCH1 LMO2 FBXW7
6 acute leukemia 32.0 TAL1 NUP98 NOTCH1 IL2
7 leukemia, acute myeloid 32.0 TAL1 NUP98 NOTCH1 LYL1 LMO2 LCK
8 lymphoma 31.7 TLX1 TAL1 NOTCH1 IL2 BCL10 BAX
9 severe combined immunodeficiency 31.5 NOTCH1 LMO2 LCK IL2
10 leukemia, chronic lymphocytic 31.3 NOTCH1 LCK IL2 BCL10 BAX ATM
11 lymphoma, non-hodgkin, familial 31.2 TAL1 NOTCH1 LCK IL2 BCL10 BAX
12 hematologic cancer 31.2 NUP98 NOTCH1 IL2 ATM ABL1
13 myelodysplastic syndrome 30.9 NUP98 NOTCH1 IL2 ATM ABL1
14 childhood t-cell acute lymphoblastic leukemia 12.9
15 refractory t lymphoblastic leukemia/lymphoma 11.8
16 t-cell adult acute lymphocytic leukemia 11.7
17 pdgfra-associated chronic eosinophilic leukemia 11.6
18 lymphosarcoma 11.6
19 leukemia, t-cell, chronic 10.8
20 leukemia, acute lymphoblastic 3 10.8
21 myeloid leukemia 10.7
22 breast liposarcoma 10.6 NOTCH1 IL2
23 interleukin-7 receptor alpha deficiency 10.6
24 combined t cell and b cell immunodeficiency 10.6 NOTCH1 LMO2 LCK IL2 ATM
25 adult acute lymphocytic leukemia 10.6
26 adenoiditis 10.6 NOTCH1 BCL10
27 b-cell lymphoma 10.5
28 glucocorticoid resistance, generalized 10.5
29 b-lymphoblastic leukemia/lymphoma with iamp21 10.5 TLX3 ABL1
30 ovarian serous cystadenocarcinoma 10.5 FBXW7 BAX ATM
31 leukemia, chronic myeloid 10.5
32 graft-versus-host disease 10.5
33 helix syndrome 10.5
34 childhood acute lymphocytic leukemia 10.5
35 ataxia-telangiectasia 10.4
36 lung disease, immunodeficiency, and chromosome breakage syndrome 10.4
37 adult t-cell leukemia 10.4
38 pancytopenia 10.4
39 telangiectasis 10.4
40 myeloproliferative neoplasm 10.4
41 acute kidney failure 10.4
42 chromosomal triplication 10.4
43 ataxia and polyneuropathy, adult-onset 10.3
44 wilms tumor 5 10.3
45 neutropenia 10.3
46 histiocytosis 10.3
47 47,xyy 10.3
48 acute graft versus host disease 10.3
49 splenomegaly 10.3
50 wilms tumor 1 10.3
51 lymphoma, hodgkin, classic 10.3
52 thymoma, familial 10.3
53 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.3
54 langerhans cell histiocytosis 10.3
55 deficiency anemia 10.3
56 hyperuricemia 10.3
57 thymoma 10.3
58 childhood leukemia 10.3
59 cataract 38 10.2 OLIG2 ATM
60 fanconi anemia, complementation group a 10.2
61 myeloma, multiple 10.2
62 acute promyelocytic leukemia 10.2
63 aspergillosis 10.2
64 anaplastic large cell lymphoma 10.2
65 follicular lymphoma 10.2
66 cutaneous t cell lymphoma 10.2
67 lymphoproliferative syndrome 10.2
68 hemopericardium 10.2
69 pericardial effusion 10.2
70 subleukemic leukemia 10.2
71 pure red-cell aplasia 10.2
72 thrombocytopenia 10.2
73 pancreatitis 10.2
74 aleukemic leukemia cutis 10.2
75 paraplegia 10.2
76 hepatoblastoma 10.2
77 chronic kidney disease 10.2
78 pediatric t-cell leukemia 10.2
79 t-cell prolymphocytic leukemia 10.2
80 red cell aplasia 10.2
81 diffuse large b-cell lymphoma 10.2
82 alzheimer disease 10.0
83 autoimmune disease 10.0
84 breast cancer 10.0
85 hypertriglyceridemia, familial 10.0
86 mastocytosis, cutaneous 10.0
87 medulloblastoma 10.0
88 polykaryocytosis inducer 10.0
89 retinal detachment 10.0
90 retinoblastoma 10.0
91 thrombophilia due to thrombin defect 10.0
92 anemia, autoimmune hemolytic 10.0
93 fanconi anemia, complementation group d2 10.0
94 immune deficiency disease 10.0
95 spondylometaphyseal dysplasia, sedaghatian type 10.0
96 myasthenia gravis 10.0
97 mycosis fungoides 10.0
98 ocular motor apraxia 10.0
99 borjeson-forssman-lehmann syndrome 10.0
100 retinitis pigmentosa 11 10.0
101 omenn syndrome 10.0
102 sickle cell anemia 10.0
103 fanconi anemia, complementation group d1 10.0
104 meningioma, radiation-induced 10.0
105 meningioma, familial 10.0
106 juvenile myelomonocytic leukemia 10.0
107 aplastic anemia 10.0
108 intraocular pressure quantitative trait locus 10.0
109 ewing sarcoma 10.0
110 hermansky-pudlak syndrome 5 10.0
111 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.0
112 autoimmune lymphoproliferative syndrome, type v 10.0
113 hemophagocytic lymphohistiocytosis 10.0
114 hyperphosphatemia 10.0
115 autosomal recessive disease 10.0
116 mantle cell lymphoma 10.0
117 peripheral t-cell lymphoma 10.0
118 infective endocarditis 10.0
119 generalized epilepsy with febrile seizures plus 10.0
120 adams-oliver syndrome 10.0
121 thrombosis 10.0
122 autosomal dominant non-syndromic intellectual disability 1 10.0
123 autosomal dominant non-syndromic intellectual disability 2 10.0
124 cytomegalovirus retinitis 10.0
125 chronic eosinophilic leukemia 10.0
126 thymus lymphoma 10.0
127 neuroretinitis 10.0
128 osteomyelitis 10.0
129 endocarditis 10.0
130 prolymphocytic leukemia 10.0
131 interstitial nephritis 10.0
132 intracranial aneurysm 10.0
133 strongyloidiasis 10.0
134 disseminated intravascular coagulation 10.0
135 spinal meningioma 10.0
136 cardiac tamponade 10.0
137 patau syndrome 10.0
138 nephrotic syndrome 10.0
139 cryptococcosis 10.0
140 retinal ischemia 10.0
141 guillain-barre syndrome 10.0
142 leukostasis 10.0
143 facial paralysis 10.0
144 toxic shock syndrome 10.0
145 urticaria 10.0
146 neovascular glaucoma 10.0
147 retinal vein occlusion 10.0
148 pericarditis 10.0
149 hyperostosis 10.0
150 blood platelet disease 10.0
151 central retinal vein occlusion 10.0
152 acute pancreatitis 10.0
153 antiphospholipid syndrome 10.0
154 embryonal rhabdomyosarcoma 10.0
155 rhabdomyosarcoma 10.0
156 central nervous system disease 10.0
157 cellulitis 10.0
158 retinitis 10.0
159 skin disease 10.0
160 hermansky-pudlak syndrome 10.0
161 spongiotic dermatitis 10.0
162 juvenile xanthogranuloma 10.0
163 subacute bacterial endocarditis 10.0
164 secretory meningioma 10.0
165 lymphoplasmacyte-rich meningioma 10.0
166 familial retinoblastoma 10.0
167 kidney disease 10.0
168 peripheral nervous system disease 10.0
169 hemolytic anemia 10.0
170 nephrolithiasis 10.0
171 connective tissue disease 10.0
172 neuroblastoma 10.0
173 polycythemia 10.0
174 nervous system disease 10.0
175 myeloid sarcoma 10.0
176 neuropathy 10.0
177 neurofibromatosis 10.0
178 learning disability 10.0
179 exophthalmos 10.0
180 acute myeloblastic leukemia with maturation 10.0
181 acute myeloblastic leukemia without maturation 10.0
182 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.0
183 bone marrow necrosis 10.0
184 chromosome 12p deletion 10.0
185 chronic graft versus host disease 10.0
186 cytokine deficiency 10.0
187 desmoplastic small round cell tumor 10.0
188 febrile ulceronecrotic mucha-habermann disease 10.0
189 homologous wasting disease 10.0
190 human t-cell leukemia virus type 1 10.0
191 polymyositis 10.0
192 aneurysm 10.0
193 headache 10.0
194 paresthesia 10.0
195 t-cell non-hodgkin lymphoma 10.0
196 rapidly involuting congenital hemangioma 10.0
197 acute monoblastic/monocytic leukemia 10.0
198 histiocytic sarcoma 10.0
199 thrombotic microangiopathy 10.0
200 burkitt lymphoma 9.9
201 gallbladder disease 1 9.9
202 calcinosis 9.9
203 cholecystitis 9.9
204 splenic abscess 9.9
205 acalculous cholecystitis 9.9
206 cll/sll 9.9
207 argyria 9.9
208 kala-azar 1 9.9
209 bacterial infectious disease 9.9
210 leishmaniasis 9.9
211 encephalitis 9.9
212 myelofibrosis 9.8
213 paragangliomas 3 9.8
214 post-transplant lymphoproliferative disease 9.8

Graphical network of the top 20 diseases related to T-Cell Acute Lymphoblastic Leukemia:



Diseases related to T-Cell Acute Lymphoblastic Leukemia

Symptoms & Phenotypes for T-Cell Acute Lymphoblastic Leukemia

MGI Mouse Phenotypes related to T-Cell Acute Lymphoblastic Leukemia:

45 (showing 8, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 ABL1 ATM BAX BCL10 FBXW7 IL2
2 hematopoietic system MP:0005397 10.21 ABL1 ATM BAX BCL10 FBXW7 IL2
3 immune system MP:0005387 10.17 ABL1 ATM BAX BCL10 FBXW7 IL2
4 embryo MP:0005380 10.1 ABL1 ATM BCL10 FBXW7 LCK LMO2
5 mortality/aging MP:0010768 10.1 ABL1 ATM BAX BCL10 FBXW7 IL2
6 nervous system MP:0003631 9.77 ABL1 ATM BAX BCL10 FBXW7 LMO2
7 neoplasm MP:0002006 9.76 ATM BAX FBXW7 IL2 LMO2 NOTCH1
8 respiratory system MP:0005388 9.17 ABL1 BAX FBXW7 IL2 NOTCH1 OLIG2

Drugs & Therapeutics for T-Cell Acute Lymphoblastic Leukemia

Drugs for T-Cell Acute Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 150, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
3
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
5
Vincristine Approved, Investigational Phase 2, Phase 3 57-22-7, 2068-78-2 5978
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
Pegaspargase Approved, Investigational Phase 2, Phase 3 130167-69-0
8
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
9
Methotrexate Approved Phase 2, Phase 3 59-05-2, 1959-05-2 126941
10
Mercaptopurine Approved Phase 2, Phase 3 50-44-2 667490
11
Ichthammol Approved Phase 3 8029-68-3
12
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
13
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3 147-94-4, 65-46-3 6253
14
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
15
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
16
Daunorubicin Approved Phase 3 20830-81-3 30323
17
Thioguanine Approved Phase 3 154-42-7 2723601
18
Ifosfamide Approved Phase 3 3778-73-2 3690
19
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
20
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
21
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
22
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
23 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
24
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
25
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
26
Amsacrine Approved, Investigational Phase 2, Phase 3 51264-14-3 2179
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
28
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
29
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
30
Cortisone Experimental Phase 3 53-06-5 222786
31
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
32 Cardiotonic Agents Phase 3
33 razoxane Phase 3
34 Gastrointestinal Agents Phase 2, Phase 3
35 Antineoplastic Agents, Hormonal Phase 2, Phase 3
36 Hormones Phase 2, Phase 3
37 Antiemetics Phase 2, Phase 3
38 Hormone Antagonists Phase 2, Phase 3
39 glucocorticoids Phase 2, Phase 3
40 Anti-Inflammatory Agents Phase 2, Phase 3
41 Folic Acid Antagonists Phase 2, Phase 3
42 Immunosuppressive Agents Phase 2, Phase 3
43 Vitamin B Complex Phase 2, Phase 3
44 Alkylating Agents Phase 2, Phase 3
45 Folate Phase 2, Phase 3
46 Anti-Infective Agents Phase 2, Phase 3
47 Anti-Bacterial Agents Phase 3
48
Liposomal doxorubicin Phase 3 31703
49 Dermatologic Agents Phase 2, Phase 3
50 Immunologic Factors Phase 2, Phase 3
51 Antiviral Agents Phase 2, Phase 3
52 Tubulin Modulators Phase 2, Phase 3
53 Antirheumatic Agents Phase 2, Phase 3
54 Antimetabolites Phase 2, Phase 3
55 Antibiotics, Antitubercular Phase 3
56 Antimitotic Agents Phase 2, Phase 3
57 Vitamin B9 Phase 2, Phase 3
58
asparaginase Phase 2, Phase 3
59 2-Aminopurine Phase 3
60 Micronutrients Phase 3
61 Trace Elements Phase 3
62 Vitamins Phase 3
63 Hematinics Phase 3
64 Antidotes Phase 3
65 Hydrocortisone-17-butyrate Phase 3
66 Nutrients Phase 3
67
Isophosphamide mustard Phase 3 0
68 Etoposide phosphate Phase 2, Phase 3
69 Podophyllotoxin Phase 3 518-28-5
70 Calcium, Dietary Phase 3
71 Keratolytic Agents Phase 3
72 Protective Agents Phase 3
73 N-Methylaspartate Phase 3
74 Methylprednisolone Acetate Phase 2, Phase 3
75 Neuroprotective Agents Phase 2, Phase 3
76
Calcium Nutraceutical Phase 3 7440-70-2 271
77
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
78
alemtuzumab Approved, Investigational Phase 2 216503-57-0
79
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
80
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
81
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
82
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
83
Montelukast Approved Phase 2 158966-92-8 5281040
84
Idarubicin Approved Phase 2 58957-92-9 42890
85
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
86
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
87
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
88
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
89
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
90
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
91
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
92
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
93
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
94
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
95
Histamine Approved, Investigational Phase 2 51-45-6 774
96
Promethazine Approved, Investigational Phase 2 60-87-7 4927
97
Acetaminophen Approved Phase 2 103-90-2 1983
98
Sodium citrate Approved, Investigational Phase 2 68-04-2
99
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
100
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
101
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
102
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
103 Molgramostim Investigational Phase 1, Phase 2 99283-10-0
104 Triamcinolone diacetate Phase 2
105 triamcinolone acetonide Phase 2
106 Triamcinolone hexacetonide Phase 2
107 Immunotoxins Phase 2
108 Antibodies, Blocking Phase 2
109 Antineoplastic Agents, Immunological Phase 1, Phase 2
110 Immunoglobulins, Intravenous Phase 1, Phase 2
111 Respiratory System Agents Phase 2
112 Leukotriene Antagonists Phase 2
113 Anti-Asthmatic Agents Phase 2
114 Antitubercular Agents Phase 1, Phase 2
115 Antifungal Agents Phase 1, Phase 2
116 Cyclosporins Phase 1, Phase 2
117 Pharmaceutical Solutions Phase 2
118 BB 1101 Phase 2
119
protease inhibitors Phase 2
120 HIV Protease Inhibitors Phase 2
121 Hydrocortisone 17-butyrate 21-propionate Phase 2
122 Hydrocortisone hemisuccinate Phase 2
123 Adjuvants, Immunologic Phase 1, Phase 2
124 Immunoglobulins Phase 2
125 Antibodies Phase 2
126 Anesthetics Phase 2
127 Anti-Ulcer Agents Phase 2
128 Hypnotics and Sedatives Phase 2
129 Antacids Phase 2
130 Ranitidine bismuth citrate Phase 2
131 Histamine Antagonists Phase 2
132 Anti-Allergic Agents Phase 2
133
Histamine Phosphate Phase 2 51-74-1 65513
134 Citrate Phase 2
135 Antibodies, Monoclonal Phase 2
136 Analgesics, Non-Narcotic Phase 2
137 Histamine H2 Antagonists Phase 2
138 Analgesics Phase 2
139 Histamine H1 Antagonists Phase 2
140 Antipyretics Phase 2
141 Anesthetics, Local Phase 2
142 Bismuth tripotassium dicitrate Phase 2
143 Neurotransmitter Agents Phase 2
144
Bismuth Phase 2 7440-69-9 16682734 105143
145 Histone Deacetylase Inhibitors Phase 2
146
Everolimus Approved Phase 1 159351-69-6 70789204 6442177
147
Mesna Approved, Investigational Phase 1 3375-50-6 598
148 9-arabinofuranosylguanine Phase 1
149 Emetics Phase 1
150
Teniposide Approved 29767-20-2 34698

Interventional clinical trials:

(showing 50, show less)
# Name Status NCT ID Phase Drugs
1 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
2 ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
3 AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3 dexamethasone;asparaginase;Asparaginase;cyclophosphamide;cytarabine;daunorubicin;doxorubicin;Etoposide;Ifosfamide;mercaptopurine;Methotrexate;prednisone;thioguanine;Vincristine;Vindesine
4 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) Active, not recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine;Vincristine Sulfate
5 Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
6 A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology Active, not recruiting NCT01228331 Phase 2, Phase 3 Amsacrine;Clofarabine;Cyclophosphamide;Cytarabine;Daunorubicin hydrochloride;Dexamethasone;Doxorubicin hydrochloride;Etoposide phosphate;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Thioguanine;Vincristine sulfate
7 A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients Completed NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
8 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
9 A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-cell Acute Lymphoblastic Leukemia (ALL) Completed NCT00006020 Phase 2 nelarabine
10 A Phase II Study of 506U78 in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL) Completed NCT00003545 Phase 2 nelarabine
11 A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia Completed NCT00077922 Phase 2 LMB-2
12 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
13 Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed NCT00866749 Phase 2 Daunorubicin;Vincristine;PEG-asparaginase;Intrathecal Methotrexate;Cyclophosphamide;Cytarabine;Mercaptopurine;Methotrexate;Doxorubicin;Thioguanine
14 Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine Sulfate
15 A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Recruiting NCT02763384 Phase 2 BL-8040;Nelarabine
16 A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia Recruiting NCT03575325 Phase 2 CPX-351
17 A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies Recruiting NCT04033302 Phase 1, Phase 2
18 An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
19 Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Recruiting NCT03808610 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine
20 Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse Recruiting NCT03860844 Phase 2 Montelukast;Isatuximab;Dexamethasone;Fludarabine;Cytarabine;Liposomal daunorubicin;Daunorubicin;Idarubicin;Filgrastim;Mitoxantrone;Doxorubicin;Vincristine;PEG Asparaginase;Cyclophosphamide;Etoposide;Methotrexate
21 Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies Recruiting NCT03983850 Phase 1, Phase 2 Busulfan;Fludarabine;Cyclophosphamide;Mycophenolate Mofetil;Sirolimus
22 A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) Not yet recruiting NCT04315324 Phase 2 AKR1C3-activated Prodrug OBI-3424
23 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Not yet recruiting NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
24 A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens. Terminated NCT00419081 Phase 2 Forodesine Hydrochloride Sterile Solution, 5 mg/mL;Forodesine Hydrochloride Capsules (100 mg)
25 A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC Terminated NCT00981799 Phase 1, Phase 2 Nelarabine;Etoposide;Cyclophosphamide;Methotrexate;Filgrastim
26 Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL) Terminated NCT02999633 Phase 2 Isatuximab SAR650984;dexamethasone;dexamethasone;acetaminophen;ranitidine;diphenhydramine
27 A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated NCT02518750 Phase 2 Dexamethasone;Panobinostat;Liposomal vincristine;Mitoxantrone;Peg-asparaginase;Bortezomib;Intrathecal Triples;High-dose methotrexate;6-Mercaptopurine;High-dose cytarabine;Nelarabine;Cyclophosphamide;Etoposide;Clofarabine
28 An Open-label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) Withdrawn NCT03207542 Phase 2 Daratumumab
29 Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed NCT01363817 Phase 1 BMS-906024;Dexamethasone
30 A PHASE I TRIAL OF PF-03084014 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCY AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA Completed NCT00878189 Phase 1 PF-03084014
31 Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma. Completed NCT00406757 Phase 1 Nelarabine injection 400mg/m2;Nelarabine injection 650mg/m2;Nelarabine injection 1000mg/m2;Nelarabine injection 1500mg/m2
32 A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies Completed NCT01094860 Phase 1 Nelarabine
33 Aflac LL1602 ENCERT: A Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Relapsed T Cell Lymphoblastic Leukemia/Lymphoma Recruiting NCT03328104 Phase 1 Everolimus;Nelarabine;Cyclophosphamide;Etoposide
34 Phase 1 Therapy of Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen Recruiting NCT03081910 Phase 1 Fludarabine;Cytoxan
35 Cell Therapy for High Risk T-Cell Malignancies Using CD7-specific CAR Expressed On Autologous T Cells (CRIMSON) Not yet recruiting NCT03690011 Phase 1 Fludarabine;Cytoxan
36 A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma Terminated NCT00100152 Phase 1 MK0752, (Notch Inhibitor)
37 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
38 The Effect of Chemotherapy on Regulatory T Cells in Children With Acute Lymphoblastic Leukemia Unknown status NCT03413046
39 Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia Unknown status NCT00343369 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;teniposide;thioguanine;vincristine sulfate
40 Molecular Taxonomy in Pediatric Cancer- IncRNA Expression in Primary T-ALL Completed NCT01626183
41 Four Years Experience With Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. Population-based Data. Completed NCT01950286
42 Molecular Mechanisms of NOTCH Induced Transformation in T-ALL Completed NCT00899366
43 Metabolic Pathways in T-Cell Acute Lymphoblastic Leukemia (T-ALL) Completed NCT01581528
44 Biological Correlates With T-cell Acute Lymphoblastic Leukemia (T-ALL) Gene Expression and Clinical Outcome Completed NCT01295476
45 Signaling in Tumorigenesis and Immunity Completed NCT01520246
46 Compound 506U78 (NSC 686673) in Patients With Relapsed or Refractory T-Cell ALL or T-Cell Lymphoblastic Lymphoma Completed NCT00003837 nelarabine
47 Molecular Correlates of Methotrexate in Childhood ALL Completed NCT00898404
48 Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study) Completed NCT00187122 Vincristine;Daunomycin;L-Asparaginase;Cytarabine;Methotrexate;Mercaptopurine;Etoposide;Cyclophosphamide;Prednisone;Dexamethasone
49 The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia Completed NCT00016302 prednisone;vincristine sulfate;daunorubicin hydrochloride;asparaginase;methotrexate;cyclophosphamide;cytarabine;mercaptopurine;leucovorin calcium;dexamethasone;doxorubicin hydrochloride;thioguanine;nelarabine;pegaspargase
50 Translational Research - Observational Study for Identification of New Possible Prognostic Factors and Future Therapeutic Targets in Children With Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT01185886

Search NIH Clinical Center for T-Cell Acute Lymphoblastic Leukemia

Genetic Tests for T-Cell Acute Lymphoblastic Leukemia

Genetic tests related to T-Cell Acute Lymphoblastic Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Acute Lymphoblastic Leukemia 29

Anatomical Context for T-Cell Acute Lymphoblastic Leukemia

MalaCards organs/tissues related to T-Cell Acute Lymphoblastic Leukemia:

40
T Cells, Myeloid, B Cells, Bone, Bone Marrow, Brain, Lung

Publications for T-Cell Acute Lymphoblastic Leukemia

Articles related to T-Cell Acute Lymphoblastic Leukemia:

(showing 2068, show less)
# Title Authors PMID Year
1
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
2
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. 6
9531611 1998
3
Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation. 61
31906810 2020
4
COTI-2 induces cell apoptosis in pediatric acute lymphoblastic leukemia via upregulation of miR-203. 61
32063077 2020
5
Rho guanosine nucleotide exchange factors are not such bad guys after all in cancera. 61
29313423 2020
6
Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. 61
31537687 2020
7
CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. 61
32492289 2020
8
Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. 61
31822778 2020
9
Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways. 61
32479694 2020
10
Bilateral optic nerve and retinal infiltration as an initial site of relapse in a child with T-cell acute lymphoblastic leukemia. 61
32368688 2020
11
Haploidentical stem cells combined with a small dose of umbilical cord blood transplantation exert similar survival outcome of HLA-matched stem cells transplantation in T-cell acute lymphoblastic leukemia. 61
31488878 2020
12
Sending CAR T Cells after T-cell Malignancies. 61
32349973 2020
13
Mucorales DNA detection in serum specimens for early diagnosis of mucormycosis. 61
32156450 2020
14
Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia. 61
32181817 2020
15
Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. 61
31904116 2020
16
Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells. 61
32277947 2020
17
Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells. 61
31962201 2020
18
Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. 61
32501545 2020
19
Preclinical Efficacy of Humanized, non-FcγR Binding Anti-CD3 Antibodies in T-cell Acute Lymphoblastic Leukemia. 61
32483610 2020
20
Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-κB Pathways. 61
32487610 2020
21
MiR-29b-3p cooperates with miR-29c-3p to affect the malignant biological behaviors in T-cell acute lymphoblastic leukemia via TFAP2C/GPX1 axis. 61
32423796 2020
22
The Clinical and Molecular Characteristics of FLT3 Mutations in Chinese De Novo Adolescent and Adult Acute Lymphoblastic Leukemia Patients. 61
32173273 2020
23
Aggressive Langerhans cell histiocytosis transformation of T cell acute lymphoblastic leukemia detected on 18F-FDG PET/CT. 61
32504290 2020
24
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. 61
32386594 2020
25
A Novel Flow Cytometric Assay to Identify Inhibitors of RBPJ-DNA Interactions. 61
32567455 2020
26
[Dihydroartemisinin Induces Apoptosis of Human Acute T Lymphocytic Leukemia Cells by Activating Oxidative Stress]. 61
32552932 2020
27
JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. 61
32530039 2020
28
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. 61
32439800 2020
29
Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism. 61
32540572 2020
30
Secondary histiocytic sarcoma with BRAFV600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib. 61
32037654 2020
31
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. 61